PharmaLex Belgium
The computed 12-month bankruptcy probability of PharmaLex Belgium is 0.3% (very low). The 2023 annual accounts show equity of €2.46M and a net result of €578k. Equity is growing by ~44.5% per year across the filed fiscal years. Its solvency ranks better than 51% of 830 sector peers (fiscal year 2023). The company has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €2.46M |
| Net result | €578k |
| Staff (FTE) | 50 |
| Better than sector | 51% |
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.
See plans →How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 41.9% | 41.2% | |
| Net result | €578k | €28k | |
| Equity | €2.46M | €160k | |
| Staff costs | €3.97M | €158k | |
| Employees (FTE) | 50.0 | 1.7 |
Show 15 other metrics
| Fiscal year | 2023 |
|---|---|
| Deposit | volledig |
| Revenue | €6.99M |
| EBITDA | €926k |
| Net profit | €578k |
| Cash flow | €671k |
| Staff costs | €3.97M |
| Income taxes | €206k |
| Dividends | €0 |
| Total assets | €5.87M |
| Equity | €2.46M |
| Debt | €3.33M |
| of which ≤ 1y | €2.61M |
| of which > 1y | €5k |
| Working capital | €2.71M |
| Employees (FTE) | 50.0 |
| 2023 | |
|---|---|
| Current ratio | 2.04 |
| Quick ratio | 2.04 |
| Working capital ratio | 46.1% |
| Solvency | 41.9% |
| Debt / equity | 1.35 |
| Long-term debt ratio | 0.00 |
| Interest coverage | 49.07 |
| Gross margin | 99.5% |
| Net margin | 8.3% |
| ROA | 9.8% |
| ROE | 23.5% |
| EBITDA margin | 13.2% |
| Days sales outstanding | 123d |
| Days payable outstanding | 9975d |
| Inventory turnover | - |
| Days inventory (DSI) | 0d |
Full annual accounts (27 line items)
| Line item | Code | 2023 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €5.87M |
| Fixed assets | 21/28 | €548k |
| Intangible fixed assets | 21 | €333k |
| Tangible fixed assets | 22/27 | €199k |
| Financial fixed assets | 28 | €15k |
| Current assets | 29/58 | €5.32M |
| Stocks & contracts in progress | 3 | €0 |
| Amounts receivable within one year | 40/41 | €2.59M |
| Cash & bank | 54/58 | €1.92M |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €5.87M |
| Equity | 10/15 | €2.46M |
| Contributions / capital | 10/11 | €119k |
| Reserves | 13 | €121k |
| Accumulated profits (losses) | 14 | €2.22M |
| Provisions & deferred taxes | 16 | €76k |
| Amounts payable | 17/49 | €3.33M |
| Amounts payable after one year | 17 | €5k |
| Amounts payable within one year | 42/48 | €2.61M |
| Trade debts payable within one year | 44 | €941k |
| Income statement | ||
| Turnover | 70 | €6.99M |
| Operating result | 9901 | €832k |
| Financial income | 75 | €7k |
| Financial charges | 65 | €56k |
| Result before taxes | 9903 | €783k |
| Income taxes | 67/77 | €206k |
| Net result for the period | 9904 | €578k |
| Result to be appropriated | 9905 | €578k |
-
Current01-11-2024 → present
-
Current01-11-2024 → present
-
Current30-06-2023 → present
-
PHARMALEX FranceLegal entityManaging director· perm. rep.: Sophie GuillaumeState Gazette act 23024099 (20-02-2023)Current24-01-2023 → present
-
PharmaLex France SASLegal entityDirector· perm. rep.: Sophie DupontState Gazette act 25002675 (07-01-2025)Current25-10-2019 → present
4 events
- 01-11-2024 Appointed· Director
- 30-06-2023 Appointed· Director
- 01-11-2019 Appointed· Director
- 25-10-2019 Appointed· Managing director
Historic, not recently confirmed (4)
-
Not recently confirmedlast confirmed in an act from 2018
-
Not recently confirmedlast confirmed in an act from 2018
-
ORTA SOLUTIONSLegal entityDirector· perm. rep.: BOULANGER BrunoState Gazette act 18135211 (06-09-2018)Not recently confirmedlast confirmed in an act from 2018
-
ORTA SOLUTIONSLegal entityManaging director· perm. rep.: Bruno BoulangerState Gazette act 17031644 (28-02-2017)Not recently confirmedlast confirmed in an act from 2017
Former directors (11)
-
Former- → 02-01-2026
-
Former24-01-2023 → 31-10-2024
2 events
- 31-10-2024 Resigned· Director
- 24-01-2023 Appointed· Director
-
Former30-06-2023 → 31-10-2024
2 events
- 31-10-2024 Resigned· Director
- 30-06-2023 Appointed· Director
-
Former24-01-2023 → 29-06-2023
2 events
- 29-06-2023 Resigned· Director
- 24-01-2023 Appointed· Director
-
Former21-08-2018 → 24-01-2023
2 events
- 24-01-2023 Resigned· Director
- 21-08-2018 Appointed· Director
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| Deloitte Réviseurs d'EntreprisesCurrent Statutory auditor · represented by Julie Delforge |
- | 26-04-2024 → present |
Show 1 earlier auditors
| AELVOET, SAMAN & PARTNERS Company auditor · represented by Wendy Saman succeeded by Deloitte Réviseurs d'Entreprises in 2024 |
A02061 | 01-01-2023 → 26-04-2024 |
| NACE primary | Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies(70200) |
| Legal form | Public limited company(014) |
| Incorporation | 19-12-2016 |
| Status | Active |
| Postal code | 1930 |
Each band states what its claims rest on. A board seat is influence over the board, not ownership. Court mandates (receiver, interim administrator) and liquidation mandates do not link companies and are therefore absent here; they belong under Directors & mandates.
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 23772B0140/00F000 | Flanders | 6,430 m² | 1 · 2,981 m² | 10.5 m · 2 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
We know of 19 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
21-04-2026 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": true,
"object_change": false,
"effective_date": "2026-04-15",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX BELGIUM",
"legal_form": "SA"
},
"signature_regime": "joint_two",
"special_mandates": [
{
"quote": "De enige aandeelhouder verleent bijzondere volmacht aan (i) Bart Lintermans, Vincent Denoncin en elke andere advocaat van Quinz BV, advocatenkantoor met zetel te Medialaan 28B, 1800 Vilvoorde, en (ii) Ad-ministerie BV, vertegenwoordigd door Adriaan de Leeuw, met zetel te Brusselsesteenweg 66, 1860 Meise, elk afzonderlijk bevoegd en met mogelijkheid tot indeplaatsstelling, teneinde de vervulling van de formaliteiten bij een ondernemingsloket met het oog op de inschrijving/aanpassing van de gegevens in de Kruispuntbank van Ondernemingen, en, desgevallend, bij de Administratie van de Belasting over de Toegevoegde Waarde, te verzekeren.",
"holder_kbo": null,
"holder_name": "Quinz BV",
"scope_categories": [
"KBO",
"filing"
],
"with_substitution": true
},
{
"quote": "De enige aandeelhouder verleent bijzondere volmacht aan (i) Bart Lintermans, Vincent Denoncin en elke andere advocaat van Quinz BV, advocatenkantoor met zetel te Medialaan 28B, 1800 Vilvoorde, en (ii) Ad-ministerie BV, vertegenwoordigd door Adriaan de Leeuw, met zetel te Brusselsesteenweg 66, 1860 Meise, elk afzonderlijk bevoegd en met mogelijkheid tot indeplaatsstelling, teneinde de vervulling van de formaliteiten bij een ondernemingsloket met het oog op de inschrijving/aanpassing van de gegevens in de Kruispuntbank van Ondernemingen, en, desgevallend, bij de Administratie van de Belasting over de Toegevoegde Waarde, te verzekeren.",
"holder_kbo": null,
"holder_name": "Ad-ministerie BV",
"scope_categories": [
"KBO",
"tax",
"filing"
],
"with_substitution": true
}
],
"governance_change": {
"admin_delegated_added": []
}
}21-04-2026 Act object · General meeting · Seat change · Notarial deed
- Act object: DENOMINATION, STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS), SIEGE SOCIAL · PharmaLex Belgium
- General meeting: date: 2026-04-13, type: assemblée générale extraordinaire · PharmaLex Belgium
- Seat change: new_address: Weiveldlaan 3/5, 1930 Zaventem, old_address: Rue Edouard Belin 5, 1435 Mont-Saint-Guibert, effective_date: 2026-04-15 · PharmaLex Belgium
- Filing: date: 2026-04-17 · PharmaLex Belgium
- Publication: date: 2026-04-21, publication: Annexes du Moniteur belge · PharmaLex Belgium
- Notarial deed: date: 2026-04-13, firm: BERQUIN NOTAIRES, notary: Tim CARNEWAL · PharmaLex Belgium
Technical details
{
"facts": [
{
"type": "act_object",
"quote": "Objet de l\u0027acte : DENOMINATION, STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS), SIEGE SOCIAL",
"value": "DENOMINATION, STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS), SIEGE SOCIAL",
"object": null,
"subject": "e1"
},
{
"type": "general_meeting",
"quote": "Ce jour, treize avril deux mille vingt-six. (...) S\u2019EST REUNIE L\u2019assembl\u00E9e g\u00E9n\u00E9rale extraordinaire de la soci\u00E9t\u00E9 anonyme \u0022PharmaLex Belgium\u0022",
"value": {
"date": "2026-04-13",
"type": "assembl\u00E9e g\u00E9n\u00E9rale extraordinaire"
},
"object": null,
"subject": "e1"
},
{
"type": "seat_change",
"quote": "L\u2019assembl\u00E9e d\u00E9cide de transf\u00E9rer le si\u00E8ge vers 1930 Zaventem, Weiveldlaan 3/5, et ce \u00E0 partir du 15 avril 2026.",
"value": {
"new_address": "Weiveldlaan 3/5, 1930 Zaventem",
"old_address": "Rue Edouard Belin 5, 1435 Mont-Saint-Guibert",
"effective_date": "2026-04-15"
},
"object": null,
"subject": "e1"
},
{
"type": "filing",
"quote": "D\u00E9pos\u00E9 17-04-2026",
"value": {
"date": "2026-04-17"
},
"object": null,
"subject": "e1"
},
{
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 21/04/2026 - Annexes du Moniteur belge",
"value": {
"date": "2026-04-21",
"publication": "Annexes du Moniteur belge"
},
"object": null,
"subject": "e1"
},
{
"type": "notarial_deed",
"quote": "Ce jour, treize avril deux mille vingt-six. (...) Devant Tim CARNEWAL, notaire \u00E0 Bruxelles (premier canton), exer\u00E7ant sa fonction dans la soci\u00E9t\u00E9 \u0022BERQUIN NOTAIRES\u0022",
"value": {
"date": "2026-04-13",
"firm": "BERQUIN NOTAIRES",
"notary": "Tim CARNEWAL"
},
"object": "e2",
"subject": "e1"
}
],
"act_meta": {
"model_id": 40,
"extractor": "open-capture-27b-v3",
"ocr_chars": 1877,
"truncated": false,
"needs_verify": true
},
"entities": [
{
"id": "e1",
"kbo": "0667.829.063",
"kind": "company",
"name": "PharmaLex Belgium",
"attrs": {
"language": "n\u00E9erlandais",
"new_seat": "Weiveldlaan 3/5, 1930 Zaventem",
"old_seat": "Rue Edouard Belin 5, 1435 Mont-Saint-Guibert",
"legal_form": "Soci\u00E9t\u00E9 anonyme"
}
},
{
"id": "e2",
"kbo": null,
"kind": "person",
"name": "Tim CARNEWAL",
"attrs": {
"firm": "BERQUIN NOTAIRES",
"role": "notaire",
"firm_seat": "1000 Bruxelles, Avenue Lloyd George 11"
}
}
]
}24-02-2026 Change in the board of directors
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX BELGIUM",
"legal_form": "SA"
}
}20-01-2026 Menno Cillekens resigns as director
- Menno Cillekens, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Menno Cillekens",
"address": null,
"birth_date": null
},
"effective_date": "2026-01-02",
"evidence_quote": "Il ressort des r\u00E9solutions \u00E9crites de l\u0027actionnaire unique en date du 30 d\u00E9cembre 2025, que l\u0027actionnaire unique a accept\u00E9 la d\u00E9mission de Monsieur Menno Cillekens \u00E0 compter du 2 janvier 2026."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX BELGIUM",
"legal_form": "SA"
}
}07-01-2025 3 directors appointed, 2 resigning
- Menno Cillikens, Bestuurder
- Anne Peeters, Bestuurder
- Sophie Dupont, Bestuurder
- Laurent Couston, Bestuurder
- François De Witte, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Laurent Couston",
"address": null,
"birth_date": null
},
"effective_date": "2024-10-31",
"evidence_quote": "Il ressort des r\u00E9solutions prises par l\u0027actionnaire unique en date du 31 octobre 2024 que l\u0027actionnaire unique a accept\u00E9 la d\u00E9mission de Monsieur Laurent Couston \u00E0 compter du 31 octobre 2024."
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Fran\u00E7ois De Witte",
"address": null,
"birth_date": null
},
"effective_date": "2024-10-31",
"evidence_quote": "Il ressort des r\u00E9solutions prises par l\u0027actionnaire unique en date du 17 d\u00E9cembre 2024 que l\u0027actionnaire unique a accept\u00E9 la d\u00E9mission de M. Fran\u00E7ois De Witte comme administrateur de la soci\u00E9t\u00E9 \u00E0 compter du le 31 octobre 2024."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Menno Cillikens",
"address": null,
"birth_date": null
},
"effective_date": "2024-11-01",
"evidence_quote": "Ensuite, l\u0027actionnaire unique a d\u00E9cid\u00E9 de nommer les personnes suivantes comme nouveaux administrateurs de la soci\u00E9t\u00E9 et ceci \u00E0 compter du 1er novembre 2024 : Monsieur Menno Cillikens"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Anne Peeters",
"address": null,
"birth_date": null
},
"effective_date": "2024-11-01",
"evidence_quote": "Ensuite, l\u0027actionnaire unique a d\u00E9cid\u00E9 de nommer les personnes suivantes comme nouveaux administrateurs de la soci\u00E9t\u00E9 et ceci \u00E0 compter du 1er novembre 2024 : Madame Anne Peeters"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Sophie Dupont",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Pharmalex France SAS",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2024-11-01",
"evidence_quote": "Ensuite, l\u0027actionnaire unique a d\u00E9cid\u00E9 de nommer les personnes suivantes comme nouveaux administrateurs de la soci\u00E9t\u00E9 et ceci \u00E0 compter du 1er novembre 2024 : Pharmalex France SAS, repr\u00E9sent\u00E9e par Sophie Dupont, administrateur-d\u00E9l\u00E9gu\u00E9"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX BELGIUM",
"legal_form": "SA"
}
}26-04-2024 Julie Delforge appointed as statutory auditor
- Julie Delforge, Commissaris
Technical details
{
"events": [
{
"kind": "commissaris_in",
"role": "commissaris",
"person": {
"rrn": null,
"name": "Julie Delforge",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Deloitte R\u00E9viseurs d\u0027Entreprises",
"address": null,
"country": null,
"legal_form": null
},
"evidence_quote": "Il ressort des r\u00E9solutions \u00E9crites de l\u0027actionnaire unique prises en date du 21 f\u00E9vrier 2024 qu\u0027il a \u00E9t\u00E9 d\u00E9cid\u00E9 d\u0027attribuer le mandat de commissaire \u00E0 la soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e, Deloitte R\u00E9viseurs d\u0027Entreprises, dont le si\u00E8ge social se situe \u00E0 Gateway Building, Luchthaven Brussel Nationaal"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX BELGIUM",
"legal_form": "SA"
}
}16-10-2023 Transaction in capital or shares
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX BELGIUM",
"legal_form": "SA"
}
}03-08-2023 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2023-07-27",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX BELGIUM",
"legal_form": "SA"
},
"signature_regime": null,
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}26-07-2023 3 directors appointed, 1 resigning
- Christopher Gauglitz, Bestuurder
- Laurent Couston, Bestuurder
- Sophie Guillaume, Bestuurder
- Thomas Dobmeyer, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Thomas Dobmeyer",
"address": null,
"birth_date": null
},
"effective_date": "2023-06-29",
"evidence_quote": "Il ressort des r\u00E9solutions prises par l\u0027actionnaire unique en date du 29 juin 2023, que la d\u00E9mission de Monsieur Thomas Dobmeyer comme administrateur de la soci\u00E9t\u00E9 a \u00E9t\u00E9 accepter \u00E0 partir du 29 juin 2023."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Christopher Gauglitz",
"address": null,
"birth_date": null
},
"effective_date": "2023-06-30",
"evidence_quote": "En remplacement de Monsieur T. Dobmeyer, l\u0027actionnaire unique a d\u00E9cid\u00E9 de nommer Monsieur Christopher Gauglitz, \u00E9lisant domicile au si\u00E8ge de la Soci\u00E9t\u00E9, comme nouvel administrateur de la Soci\u00E9t\u00E9 \u00E0 partir du 30 juin 2023."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Laurent Couston",
"address": null,
"birth_date": null
},
"effective_date": "2023-06-30",
"evidence_quote": "Ensuite, l\u0027actionnaire unique a d\u00E9cid\u00E9 de nommer Monsieur Laurent Couston, \u00E9lisant domicile au si\u00E8ge de la Soci\u00E9t\u00E9, comme nouvel administrateur de la Soci\u00E9t\u00E9 \u00E0 partir du 30 juin 2023."
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Sophie Guillaume",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Pharmalex France SAS",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2023-06-30",
"evidence_quote": "\u00C0 partir du 30 juin 2023, le conseil d\u0027administration de la Soci\u00E9t\u00E9 se composera des personnes suivantes: \u2022 la soci\u00E9t\u00E9 de droit fran\u00E7ais \u0022Pharmalex France SAS\u0022, repr\u00E9sent\u00E9e par Sophie Guillaume;"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX BELGIUM",
"legal_form": "SA"
}
}20-02-2023 3 directors appointed, 5 resigning
- Mr. François De Witte, Bestuurder
- Mr. Thomas Dobmeyer, Bestuurder
- Sophie Guillaume, Gedelegeerd bestuurder
- Mme. Carolyn Belcher, Bestuurder
- Mme. IIze Lauberte, Bestuurder
- Mme. Caren Martini, Bestuurder
- Mr. Bruno Boulanger, Bestuurder
- Mr. Bruno Boulanger, Gedelegeerd bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Mme. Carolyn Belcher",
"address": null,
"birth_date": null
},
"effective_date": "2023-01-24",
"evidence_quote": "D\u00C9CIDE de r\u00E9voquer le mandat de : (i) Mme. Carolyn Belcher; ... en tant qu\u0027administrateurs de la Soci\u00E9t\u00E9 avec effet \u00E0 la date de ces r\u00E9solutions et de confirmer la fin de leurs mandats et de leur donner d\u00E9charge provisoire de leurs mar\u0131dats",
"discharge_granted": true
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Mme. IIze Lauberte",
"address": null,
"birth_date": null
},
"effective_date": "2023-01-24",
"evidence_quote": "D\u00C9CIDE de r\u00E9voquer le mandat de : (ii) Mme. IIze Lauberte; ... en tant qu\u0027administrateurs de la Soci\u00E9t\u00E9 avec effet \u00E0 la date de ces r\u00E9solutions et de confirmer la fin de leurs mandats et de leur donner d\u00E9charge provisoire de leurs mar\u0131dats",
"discharge_granted": true
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Mme. Caren Martini",
"address": null,
"birth_date": null
},
"effective_date": "2023-01-24",
"evidence_quote": "D\u00C9CIDE de r\u00E9voquer le mandat de : (i) Mme. Caren Martini; et ... en tant qu\u0027administrateurs de la Soci\u00E9t\u00E9 avec effet \u00E0 la date de ces r\u00E9solutions et de confirmer la fin de leurs mandats et de leur donner d\u00E9charge provisoire de leurs mar\u0131dats",
"discharge_granted": true
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Mr. Bruno Boulanger",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Orta Solutions SRL",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2023-01-24",
"evidence_quote": "D\u00C9CIDE de r\u00E9voquer le mandat de : (iv) Orta Solutions SRL, repr\u00E9sent\u00E9e par Mr. Bruno Boulanger, en tant qu\u0027administrateurs de la Soci\u00E9t\u00E9 avec effet \u00E0 la date de ces r\u00E9solutions et de confirmer la fin de leurs mandats et de leur donner d\u00E9charge provisoire de leurs mar\u0131dats",
"discharge_granted": true
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Mr. Fran\u00E7ois De Witte",
"address": null,
"birth_date": null
},
"effective_date": "2023-01-24",
"evidence_quote": "D\u00C9CIDE de nommer les personries suivantes en tant qu\u0027administrateurs de la Soci\u00E9t\u00E9, qui acceptent, \u00E0 compter de la date de ces r\u00E9solutions, et pour une p\u00E9riode ind\u00E9termin\u00E9e : (i) Mr. Fran\u00E7ois De Witte; et"
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Mr. Thomas Dobmeyer",
"address": null,
"birth_date": null
},
"effective_date": "2023-01-24",
"evidence_quote": "D\u00C9CIDE de nommer les personries suivantes en tant qu\u0027administrateurs de la Soci\u00E9t\u00E9, qui acceptent, \u00E0 compter de la date de ces r\u00E9solutions, et pour une p\u00E9riode ind\u00E9termin\u00E9e : (i) Mr. Fran\u00E7ois De Witte; et (ii) Mr. Thomas Dobmeyer."
},
{
"kind": "director_out",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Mr. Bruno Boulanger",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "Orta Solutions SRL",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2023-01-24",
"evidence_quote": "D\u00C9CIDENT de r\u00E9voquer le mandat d\u0027Orta Solutioris SRL, repr\u00E9sent\u00E9e par Mr. Bruno Boulanger, er tant qu\u0027administrateur d\u00E9l\u00E9gu\u00E9 de la Soci\u00E9t\u00E9."
},
{
"kind": "director_in",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Sophie Guillaume",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "PHARMALEX France",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2023-01-24",
"evidence_quote": "Les administrateurs de la Soci\u00E9t\u00E9 constatent ensuite que PHARMALEX France (repr\u00E9sent\u00E9e par Sophie Guillaume) est le seul administrateur d\u00E9l\u00E9gu\u00E9 de la Soci\u00E9t\u00E9."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX BELGIUM",
"legal_form": "SA"
}
}01-02-2023 Transaction in capital or shares
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX BELGIUM",
"legal_form": "SA"
}
}09-01-2023 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2023-01-01",
"legal_form_change": false
},
"bedrijfsrevisor": {
"quote": "Le rapport du r\u00E9viseur d\u0027entreprises ou l\u0027expert-comptable externe d\u00E9sign\u00E9 par la Soci\u00E9t\u00E9 \u00E0 savoir la soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e \u0022AELVOET, SAMAN \u0026 PARTNERS\u0022, ayant son si\u00E8ge \u00E0 1150 Woluwe-Saint-Pierre, Avenue Grandchamp 215 et titulaire du num\u00E9ro d\u0027entreprise 0475.820.533, repr\u00E9sent\u00E9e par Madame SAMAN Wendy, r\u00E9viseur d\u0027entreprises",
"firm_kbo": "0475.820.533",
"firm_name": "AELVOET, SAMAN \u0026 PARTNERS SRL",
"ibr_number": "A02061",
"individual_name": "Wendy Saman"
},
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX BELGIUM",
"legal_form": "SA"
},
"signature_regime": "joint_two",
"special_mandates": [
{
"quote": "L\u0027assembl\u00E9e conf\u00E8re tous pouvoirs \u00E0 (i) chaque administrateur de la Soci\u00E9t\u00E9 Absorbante et (ii) chaque collaborateur de la soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e \u0022JEAN-BERNARD LEVEUGLE\u0022, ayant son si\u00E8ge \u00E0 4342 Awans, Rue Chauss\u00E9e 62 bo\u00EEte 7, et titulaire du num\u00E9ro d\u0027entreprise 0473.392.464, qui tous, \u00E0 cet effet, \u00E9lisent domicile \u00E0 l\u0027adresse pr\u00E9cit\u00E9e, chacun agissant s\u00E9par\u00E9ment, avec droit de substitution, afin d\u0027assurer les formalit\u00E9s aupr\u00E8s d\u0027un guichet d\u0027entreprise en vue d\u0027assurer la modification des donn\u00E9es dans la Banque Carrefour des Entreprises et, le cas \u00E9ch\u00E9ant, aupr\u00E8s de l\u0027Administration de la Taxe sur la Valeur Ajout\u00E9e.",
"holder_kbo": "0473.392.464",
"holder_name": "JEAN-BERNARD LEVEUGLE",
"scope_categories": [
"KBO",
"tax",
"filing"
],
"with_substitution": true
}
],
"governance_change": {
"admin_delegated_added": []
}
}14-11-2022 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": "proposal",
"notary": {
"name": "Tim CARNEWAL",
"firm_city": null,
"firm_name": null,
"office_city": "Brabant Wallon",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2022-11-04",
"filing_date": "2022-10-28",
"act_kind_objet": "PROJET DE FUSION PAR ABSORPTION CONFORM\u00C9MENT AUX ARTICLES"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2022-10-24",
"unanimous": null
},
"conversion": null,
"detected_kind": "merger_absorption",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0667.829.063",
"name": "PharmaLex Belgium SA",
"role": "acquiring",
"address": "Rue Edouard Belin 5, 1435 Mont-Saint-Guibert",
"is_foreign": false,
"legal_form": "SA",
"is_new_company": false,
"jurisdiction_country": null
},
{
"kbo": "0828.945.370",
"name": "Archemin SRL",
"role": "absorbed",
"address": "Lange Nieuwstraat 1, 2800 Mechelen",
"is_foreign": false,
"legal_form": "SRL",
"is_new_company": false,
"jurisdiction_country": null
}
],
"exchange_ratio": 34.0,
"legal_articles": [
"12:2",
"12:24",
"12:13"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": "2021-12-31",
"exchange_ratio_text": "1 action de la Soci\u00E9t\u00E9 Absorb\u00E9e \u00E9chang\u00E9e contre 34 nouvelles actions de la Soci\u00E9t\u00E9 Absorbante",
"new_shares_issued_n": 34000,
"real_estate_included": false,
"patrimony_description": "L\u0027int\u00E9gralit\u00E9 du patrimoine de la Soci\u00E9t\u00E9 Absorb\u00E9e, y compris tous ses droits et obligations, sera transf\u00E9r\u00E9e \u00E0 la Soci\u00E9t\u00E9 Absorbante par dissolution sans liquidation.",
"equity_transferred_eur": 311599.39,
"accounting_effective_date": "2023-01-01"
},
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PharmaLex Belgium SA",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Tim CARNEWAL",
"org_rep_person_name": null
},
"summary_narrative": "Les organes d\u0027administration de PharmaLex Belgium SA et d\u0027Archemin SRL ont conjointement r\u00E9dig\u00E9 un projet de fusion par absorption, dans lequel PharmaLex Belgium SA absorbera int\u00E9gralement Archemin SRL. Cette fusion, fond\u00E9e sur la valeur nette comptable des fonds propres au 31 d\u00E9cembre 2021, pr\u00E9voit l\u0027\u00E9mission de 34.000 nouvelles actions de PharmaLex Belgium SA au profit des actionnaires d\u0027Archemin SRL, au taux de 34 actions pour 1 action. L\u0027op\u00E9ration prendra effet le 1er janvier 2023, tant sur le plan comptable que fiscal.",
"co_filed_documents": [],
"detected_real_type": "fusion_proposal",
"referenced_correction": null,
"should_reroute_to_category": null
}20-02-2020 2 directors appointed, 1 resigning
- Sophie Guillaume, Bestuurder
- Sophie Guillaume, Gedelegeerd bestuurder
- Benoît Verjans, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Beno\u00EEt Verjans",
"address": null,
"birth_date": null
},
"effective_date": "2019-11-01",
"evidence_quote": "L\u0027assembl\u00E9e G\u00E9n\u00E9rale accepte la d\u00E9mission de Beno\u00EEt Verjans, domicili\u00E9 \u00E0 Belgique, 1450 Chastre, Rue des Mottes 25, comme membre du Conseil d\u0027Administration. Il recevra d\u00E9charge pour l\u0027exercice de son mandat d\u0027administrateur lors de la prochaine assembl\u00E9e g\u00E9n\u00E9rale ordinaire, qui statuera sur les com",
"discharge_granted": false
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "Sophie Guillaume",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "PharmaLex France SAS",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2019-11-01",
"evidence_quote": "L\u0027assembl\u00E9e G\u00E9n\u00E9rale approuve \u00E0 l\u0027unanimit\u00E9 la nomination comme membre du Conseil d\u0027Administration de PharmaLex France SAS, soci\u00E9t\u00E9 par actions simplifi\u00E9e (SAS), enregistr\u00E9e au R.C.S. Nanterre sous le num\u00E9ro 821 737 996 et dont le si\u00E8ge social est situ\u00E9 au 41 rue de Villiers \u00E0 92523 Neuilly-sur-Sein"
},
{
"kind": "director_in",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Sophie Guillaume",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": null,
"name": "PharmaLex France SAS",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2019-10-25",
"evidence_quote": "Le conseil d\u0027administration d\u00E9cide \u00E0 l\u0027unanimit\u00E9 de nommer comme administrateur d\u00E9l\u00E9gu\u00E9, \u00E0 partir d\u0027aujourd\u0027hui la soci\u00E9t\u00E9 par actions simplifi\u00E9e (SAS) de droit fran\u00E7ais \u003C\u003C PharmaLex France SAS\u00BB, ayant son si\u00E8ge social \u00E0 92523 Neuilly-sur-Seine (France) Cedex, 41 rue de Villiers, enregistr\u00E9e au R.C."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX BELGIUM",
"legal_form": "SA"
}
}06-09-2018 Transaction in capital or shares
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX BELGIUM",
"legal_form": "SA"
}
}03-07-2018 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": "proposal",
"notary": {
"name": "Monsieur Verjans Benoit, Administrateur d\u00E9l\u00E9gu\u00E9",
"firm_city": null,
"firm_name": null,
"office_city": "Mont-Saint-Guibert",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2018-07-03",
"filing_date": "2018-06-21",
"act_kind_objet": "RUE EDOUARD BELIN 5, 1435 Mont-Saint-Guibert, Belgique"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2018-06-18",
"unanimous": null
},
"conversion": null,
"detected_kind": "merger_absorption",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0667.829.063",
"name": "PHARMALEX",
"role": "acquiring",
"address": "Rue Edouard Belin 35, 1435 Mont-Saint-Guibert, Belgique",
"is_foreign": false,
"legal_form": "SA",
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": "0480.272.437",
"name": "ARLENDA",
"role": "absorbed",
"address": "Rue Edouard Belin 35, 1435 Mont-Saint-Guibert, Belgique",
"is_foreign": false,
"legal_form": "SA",
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"12:7",
"12:50",
"719",
"676"
],
"is_cross_border": false,
"is_silent_merger": true,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "La totalit\u00E9 des actifs et passifs de la soci\u00E9t\u00E9 absorb\u00E9e (ARLENDA) sera transf\u00E9r\u00E9e \u00E0 la soci\u00E9t\u00E9 absorbante (PHARMALEX). Le transfert concerne l\u0027ensemble du patrimoine, y compris les activit\u00E9s li\u00E9es au d\u00E9veloppement, \u00E0 la production et \u00E0 la commercialisation de technologies d\u0027analyse de donn\u00E9es, ainsi que les prestations de conseil, d\u0027expertise et de formation.",
"equity_transferred_eur": null,
"accounting_effective_date": "2018-07-01"
},
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Monsieur Verjans Benoit",
"org_rep_person_name": null
},
"summary_narrative": "Les organes de gestion des soci\u00E9t\u00E9s anonymes PHARMALEX et ARLENDA ont \u00E9tabli conjointement un projet de fusion par absorption conform\u00E9ment aux articles 676 et 719 du Code des Soci\u00E9t\u00E9s. La soci\u00E9t\u00E9 PHARMALEX, qui d\u00E9tient 100 % des actions d\u0027ARLENDA, absorbera enti\u00E8rement son patrimoine. Les op\u00E9rations de la soci\u00E9t\u00E9 absorb\u00E9e seront comptablement consid\u00E9r\u00E9es comme r\u00E9alis\u00E9es au nom de la soci\u00E9t\u00E9 absorbante \u00E0 compter du 1er juillet 2018. Aucun rapport d\u0027\u00E9change n\u0027est requis car la soci\u00E9t\u00E9 absorbante est d\u00E9j\u00E0 propri\u00E9taire de toutes les actions de la soci\u00E9t\u00E9 absorb\u00E9e.",
"co_filed_documents": [],
"detected_real_type": "fusion_proposal",
"referenced_correction": null,
"should_reroute_to_category": null
}28-02-2017 2 directors appointed
- VERJANS Benoît, Gedelegeerd bestuurder
- Bruno Boulanger, Gedelegeerd bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "VERJANS Beno\u00EEt",
"address": null,
"birth_date": null
},
"effective_date": "2017-01-25",
"evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide \u00E0 l\u0027unanimit\u00E9 de nommer comme administrateurs d\u00E9l\u00E9gu\u00E9s, \u00E0 partir d\u0027aujourd\u0027hui: 1/ Monsieur VERJANS Beno\u00EEt, domicili\u00E9 \u00E0 1050 Bruxelles, rue de la Natation 30."
},
{
"kind": "director_in",
"role": "gedelegeerd_bestuurder",
"person": {
"rrn": null,
"name": "Bruno Boulanger",
"address": null,
"birth_date": null
},
"via_org": {
"kbo": "0825678747",
"name": "SPRL \u0027Orta Solutions\u0027",
"address": null,
"country": null,
"legal_form": null
},
"effective_date": "2017-01-25",
"evidence_quote": "2/ La SPRL \u0027Orta Solutions\u0027, ayant son si\u00E8ge social \u00E0 1348 Louvain-La-Neuve, Place Victor Horta 71, immatricul\u00E9e au Registre des Personnes Morales \u00E0 Nivelles et aupr\u00E8s de la TVA sous le num\u00E9ro BE 0825.678.747, repr\u00E9sent\u00E9e - conform\u00E9ment \u00E0 l\u0027article 61 \u00A72 du Code des Soci\u00E9t\u00E9s - par son repr\u00E9sentant p"
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX BELGIUM",
"legal_form": "SA"
}
}14-02-2017 1 director appointed, 2 resigning
- VERJANS Benoît, Bestuurder
- DOBMEYER Thomas Stefan, Bestuurder
- MARTINI Caren Ingrid, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "DOBMEYER Thomas Stefan",
"address": null,
"birth_date": null
},
"effective_date": "2016-12-21",
"evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide de d\u00E9missionner comme administrateur, \u00E0 partir d\u0027aujourd\u0027hui: -Monsieur DOBMEYER Thomas Stefan, domicili\u00E9 \u00E0 60528 Frankfurt (Allemagne), Reichsforststra\u00DFe 31. Il est d\u00E9missionn\u00E9 honorablement",
"discharge_granted": true
},
{
"kind": "director_out",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "MARTINI Caren Ingrid",
"address": null,
"birth_date": null
},
"effective_date": "2016-12-21",
"evidence_quote": "Madame MARTINI Caren Ingrid, domicili\u00E9e \u00E0 65779 Kelkheim, Taunus (Germany), Glogauerstra\u00DFe 15. Elle est d\u00E9mission\u00E9e honorablement.",
"discharge_granted": true
},
{
"kind": "director_in",
"role": "bestuurder",
"person": {
"rrn": null,
"name": "VERJANS Beno\u00EEt",
"address": null,
"birth_date": null
},
"effective_date": "2016-12-21",
"evidence_quote": "L\u0027assembl\u00E9e nomme comme administrateur, \u00E0 partir d\u0027aujourd\u0027hui pour une dur\u00E9e de six ann\u00E9es, jusqu\u0027\u00E0 l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire de 2022: -Monsieur VERJANS Beno\u00EEt, domicili\u00E9 \u00E0 1050 Bruxelles, rue de la Natation 30. II d\u00E9clare accepter son mandat."
}
],
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PHARMALEX BELGIUM",
"legal_form": "SA"
}
}21-12-2016 Incorporation of a new SNC
Technical details
{
"kind": "oprichting",
"seat": "1090 Jette, Avenue du Bourgmestre Etienne Demunter 5 b 4",
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"founders": [
{
"org": {
"kbo": null,
"name": "PharmaLex GmbH"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "capital",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "PharmaLex GmbH",
"contribution_type": "cash",
"amount_paid_in_eur": 99999,
"holder_person_name": null,
"is_subscriber_only": false,
"n_shares_subscribed": 99999,
"amount_subscribed_eur": 99999,
"is_anonymous_silent_partner": false
},
{
"org": {
"kbo": null,
"name": "PharmaLex Holding GmbH"
},
"kind": "rechtspersoon",
"person": null,
"share_class": "capital",
"partner_role": null,
"holder_org_kbo": null,
"holder_org_name": "PharmaLex Holding GmbH",
"contribution_type": "cash",
"amount_paid_in_eur": 1,
"holder_person_name": null,
"is_subscriber_only": true,
"n_shares_subscribed": 1,
"amount_subscribed_eur": 1,
"is_anonymous_silent_partner": false
}
],
"capital_eur": 100000,
"subject_company": {
"kbo": "0667.829.063",
"name_full": "PharmaLex Belgium",
"legal_form": "SNC"
},
"initial_directors": [],
"incorporation_date": "2016-12-15",
"post_incorporation_mandates": []
}| Legal nameFR | PharmaLex Belgium |
| Legal nameNL | PharmaLex Belgium |